These minor changes are often made solely to create the illusion that the patient requires a unique compounded formulation when, in reality, they do not. Whats particularly telling is that many compounding pharmacies are offering the same additives or minor adjustments to large numbers of patientsi.e., mass personalizationwhich clearly demonstrates a violation of FDA requirements for individualized compounding. FDA, Eli Lilly and Novo Nordisk Agree on Compounded GLP-1 Medications The FDA makes it clear: providers should not sell or market compounded GLP-1 medications like semaglutide and tirzepatide unless a patient has a legitimate, documented clinical need
Drawing on health records from Ontario, Canada, researchers at the University of Toronto analyzed nearly 140,000 adults with type 2 diabetes to investigate a possible link between GLP-1 use and wet AMD
Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial
Its critical in DNA synthesis, red blood cell formation, and neurological function
Jenkins, N
Dutta D, Nagendra L, Harish BG, Sharma M, Joshi A, Hathur B, et al